



Contents lists available at ScienceDirect

## Biochimica et Biophysica Acta

journal homepage: [www.elsevier.com/locate/bbagen](http://www.elsevier.com/locate/bbagen)

## Review

Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes<sup>☆</sup>Sho-ichi Yamagishi<sup>a,\*</sup>, Sayaka Maeda<sup>a</sup>, Takanori Matsui<sup>a</sup>, Seiji Ueda<sup>b</sup>, Kei Fukami<sup>b</sup>, Seiya Okuda<sup>b</sup><sup>a</sup> Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830-0011, Japan<sup>b</sup> Department of Medicine, Kurume University School of Medicine, Kurume, Japan

## ARTICLE INFO

## Article history:

Received 13 January 2011

Accepted 21 March 2011

Available online xxxx

## Keywords:

AGE

Oxidative stress

RAGE

Diabetic vascular complication

## ABSTRACT

A non-enzymatic reaction between reducing sugars and amino groups of proteins, lipids and nucleic acids contributes to the aging of macromolecules, whose process has been known to progress at an accelerated rate under hyperglycemic and/or oxidative stress conditions. Over a course of days to weeks, early glycation products undergo further reactions such as rearrangements and dehydration to become irreversibly cross-linked, fluorescent protein derivatives termed advanced glycation end products (AGEs). AGEs elicit oxidative stress generation and subsequently cause inflammatory and thrombogenic reactions in various types of cells via interaction with a receptor for AGEs (RAGE), thereby being involved in vascular complications in diabetes. In addition, mitochondrial superoxide generation has been shown to play an important role in the formation and accumulation of AGEs under diabetic conditions. Further, we have recently found that a pathophysiological crosstalk between AGE–RAGE axis and renin–angiotensin system (RAS) could contribute to the progression of vascular damage in diabetes. These observations suggest that inhibition of AGE–RAGE–oxidative stress axis or blockade of its interaction with RAS is a novel therapeutic strategy for preventing vascular complications in diabetes. In this paper, we review the role of AGE–oxidative stress axis and its therapeutic interventions in vascular complications in diabetes. This article is part of a Special Issue entitled: Biochemistry of Mitochondria.

© 2011 Published by Elsevier B.V.

## 1. Introduction

Diabetic retinopathy and nephropathy are the leading causes of acquired blindness and end-stage renal disease (ESRD), respectively, which could account for disabilities in patients with diabetes [1,2]. Also, in Japan, about 14,000 people per year become ESRD due to diabetes, and its number is still increasing. Further, cardiovascular disease (CVD) accounts for about 30–40% of death in diabetic patients in Japan, and average life span in diabetic patients is about 9–13-years shorter, compared with non-diabetic subjects. Two landmark clinical studies, Diabetes Control and Complication Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) [3,4] have shown that intensive blood glucose or blood pressure (BP) control significantly reduces the risk for the development and progression of vascular complications in diabetes. However, strict control of blood glucose is often difficult to maintain and may increase the risk of hypoglycemia. Moreover, current therapeutic options for the treatment of hypertension are far from satisfactory in diabetes. Therefore, to develop novel therapeutic strategies that specifically target vascular complications in diabetes is actually desired.

Various hyperglycemia-elicited metabolic and hemodynamic derangements such as increased formation of advanced glycation end products (AGEs), enhanced production of reactive oxygen species (ROS), stimulation of protein kinase C (PKC), and the activation of the renin–angiotensin system (RAS) have been proposed to contribute to vascular complications in diabetes [1,2]. However, which molecular pathway is the most dominant one remains to be clarified. Meanwhile, a recent follow-up study after DCCT, called DCCT–Epidemiology of Diabetes Interventions and Complications (DCCT–EDIC) Research, has provided us with a clue to the solution of this problem. In this trial, all patients had received intensive therapy. Therefore, the differences of blood glucose control between original intensive therapy group and conventional one were abolished a couple of years after the end of DCCT trial. However, those who had been on original intensive therapy still maintained their advantage in terms of reduced risk of the development and progression of diabetic nephropathy and retinopathy during the EDIC periods, despite hyperglycemia [5,6]. Intensive therapy during the DCCT resulted in decreased progression of intima-media thickness and subsequently reduced the risk of nonfatal myocardial infarction, stroke, or death from cardiovascular disease by 57% 11 years after the end of the trials [7,8]. Further, a recent follow-up study of UKPDS, called UKPDS80, also has shown that benefits of an intensive therapy in patients with type 2 diabetes are sustained after the cessation of the trial [9]. In this

<sup>☆</sup> This article is part of a Special Issue entitled: Biochemistry of Mitochondria.

\* Corresponding author. Tel.: +81 942 31 7580; fax: +81 942 31 7707.

E-mail address: [shoichi@med.kurume-u.ac.jp](mailto:shoichi@med.kurume-u.ac.jp) (S. Yamagishi).

study, despite an early loss of glycemic differences between original intensive therapy group and conventional one, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up [9]. These findings demonstrate that so-called 'metabolic memory' could cause chronic abnormalities and exert carry-over effects in diabetic vessels that are not easily reversed, even by subsequent, relatively good control of blood glucose. In other words, these observations suggest a long-term beneficial influence of early metabolic control, that is, legacy effect on the risk of vascular complications and death in both type 1 and type 2 diabetic patients. Among the various biochemical pathways implicated in vascular complications in diabetes, biochemical nature of AGEs and their mode of action are most compatible with the concept of 'metabolic memory' [10–12].

The concept of AGEs was first built up by a French chemist, L.C. Maillard a century ago [10–12]. He reported that brown-fluorescent products were generated when amino acids were heated with reducing sugars. Since then, food chemists have long studied this process as a source of flavor, color, and texture changes in cooked or stored foods. But, in 1980s, it was realized that this process could also occur *in vivo* [10–12].

Reducing sugars such as glucose can react non-enzymatically with amino groups of proteins to form Amadori products [12–14]. Over the course of days to weeks, these Amadori products undergo further rearrangement reactions to form irreversibly cross-linked senescent macroprotein derivatives called AGEs. The formation and accumulation of AGEs have been known to progress at an accelerated rate under diabetes. AGEs are hardly degraded and remain for a long time in diabetic tissues even if glycemic control is improved. There is accumulating evidence that AGEs elicit oxidative stress generation in various types of cells through the interaction with a receptor for AGEs (RAGE) and subsequently evoke inflammatory and thrombogenic reactions, thereby playing an important role in the development and progression of vascular complications in diabetes [14–18]. Further, AGEs are reported to up-regulate RAGE expression in various cell types and induce sustained activation of transcriptional factor nuclear factor- $\kappa$ B (NF- $\kappa$ B) [17]. Therefore, it is conceivable that the AGE–RAGE-induced oxidative stress generation further potentiates the formation and accumulation of AGEs and subsequent RAGE overexpression in diabetes. These positive feedback loops between AGEs and RAGE-downstream pathways could make a vicious cycle, thus providing a mechanistic basis for understanding why there could exist the phenomenon of 'metabolic memory' in vascular complications in diabetes. In addition, we have recently found that a pathophysiological crosstalk between AGE–RAGE axis and RAS could contribute to the progression of vascular damage in diabetes as well [19]. Taken together, these observations suggest that inhibition of AGE–RAGE-oxidative stress axis or blockade of its interaction with RAS is a novel therapeutic strategy for preventing vascular complications in diabetes. In this paper, we review the pathophysiological role of AGE–oxidative stress axis and its therapeutic interventions in vascular complications in diabetes.

## 2. Role of AGEs, RAS and pigment epithelium-derived factor (PEDF) in diabetic retinopathy

### 2.1. Pericyte loss and dysfunction

Pericytes are elongated cells of the mesodermal origin, wrapping around and along endothelial cells (ECs) of small vessels [20]. The earliest histopathological hallmark of diabetic retinopathy is loss of pericytes [20]. In parallel with loss of pericytes, several characteristic changes including thickening of the basement membrane, hyperpermeability, and microaneurysm formation are observed [20]. Since pericytes have played an important role in the maintenance of

microvascular homeostasis, loss of pericytes could predispose the vessels to angiogenesis, thrombogenesis and EC injury, thus leading to full-blown clinical expression of diabetic retinopathy [1].


Retinal pericytes accumulate AGEs during diabetes [21], which would be expected to have a detrimental influence on pericyte survival and function in diabetes. Indeed, AGE–RAGE-mediated ROS generation has been shown to induce apoptotic cell death of retinal pericytes by increasing the activity of caspase-3, a key enzyme in the execution of apoptosis [22,23]. Further, we have found that beraprost sodium, a prostacyclin analog or forskolin, an activator of adenylate cyclase protects against the AGE-induced pericyte apoptosis by suppressing ROS generation and subsequent RAGE overexpression [24]. Since cyclic AMP elevating agents were known to block ROS generation in neutrophils by inhibiting reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity [25], NADPH oxidase might be a source of ROS production elicited by AGEs and be a target of beraprost sodium.

Pericyte dysfunction has also been considered one of the characteristic features of the early phase of diabetic retinopathy [1]. AGEs act on pericytes to stimulate vascular endothelial growth factor (VEGF) expression [23]. VEGF is a specific mitogen to ECs, also known as vascular permeability factor, and is thought to be a pivotal factor in the pathogenesis of proliferative diabetic retinopathy [26]. Furthermore, retinal VEGF level was found to be associated with the breakdown of the blood–retinal barrier, thus being involved in vascular hyperpermeability in background retinopathy [27,28]. These observations suggest that AGEs might be involved in diabetic retinopathy by inducing VEGF overexpression in pericytes as well.

The local RAS is activated under diabetes [29]. Angiotensin II (Ang II) stimulated intracellular ROS generation, decreased DNA synthesis and simultaneously up-regulated VEGF mRNA levels in cultured retinal pericytes, all of which are blocked by the treatment with telmisartan, an Ang II type 1 receptor blocker (ARB) or an antioxidant, *N*-acetylcysteine (NAC) [30,31]. Further, Ang II has been shown to potentiate the deleterious effects of AGEs on pericytes by inducing RAGE expression [32]. *In vivo*, AGE injection stimulated RAGE expression in the eye of spontaneously hypertensive rats, which was blocked by telmisartan. *In vitro*, Ang II-type 1 receptor-mediated ROS generation elicited RAGE gene expression in retinal pericytes through NF- $\kappa$ B activation [32]. In addition, Ang II augmented the AGE-induced pericyte apoptosis [32]. These findings suggest the pathophysiological crosstalk between the AGE–RAGE–oxidative stress axis and the RAS in pericyte loss and dysfunction.

Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily of serine protease inhibitors with complex neurotrophic, neuroprotective, anti-angiogenic, anti-oxidative and anti-inflammatory properties, any of which could potentially be exploited as a therapeutic option for the treatment of vascular complications in diabetes [33–37]. PEDF inhibited the AGE-induced ROS generation and subsequently prevented apoptotic cell death of pericytes by restoring bcl-2 gene expression [23]. Further, we have found that anti-PEDF antibodies inhibit the growth-stimulating effects of co-cultured ECs on pericytes [38,39]. These observations suggest that PEDF could be an EC-derived mitogen or survival factor for retinal pericytes. In addition, since Ang II-type 1 receptor interaction decreased PEDF mRNA levels in ECs, suppression of EC-derived PEDF production by Ang II may also be involved in progression of diabetic retinopathy. Taken together, these findings suggest that blockade of the pathophysiological crosstalk between the AGE–RAGE system and the RAS or substitution of PEDF proteins might be a promising therapeutic strategy for preventing pericyte loss and dysfunction at early phase of diabetic retinopathy (Fig. 1).

In animal studies, treatment of diabetic rats for 26 weeks with aminoguanidine, an inhibitor of AGE formation, prevented a 2.6-fold accumulation of AGEs at branching sites of pre-capillary arterioles and thereby prevented abnormal EC proliferation and significantly



**Fig. 1.** Role of AGE–RAGE axis and RAS in early diabetic nephropathy. Ang II, Angiotensin II; GPx, glutathione peroxidase; AT1 receptor, Ang II type 1 receptor; NAC, N-acetylcysteine.

diminished pericyte dropout [40]. The derivative of vitamin B<sub>6</sub>, pyridoxamine, a specific post-Amadori inhibitor, has also been shown to prevent retinal capillary dropout in experimental diabetic retinopathy [41]. Moreover, an anti-oxidant,  $\alpha$ -lipoic acid administration decreased retinal 8-hydroxy-2'-deoxyguanosine (8-OHdG) and nitrotyrosine levels and subsequently inhibited retinal capillary cell apoptosis in streptozotocin-induced diabetic rats [42]. These observations further suggest the active participation of the AGE–RAGE-mediated ROS generation in pericyte loss in diabetic retinopathy.

## 2.2. Hyperpermeability, inflammation, thrombosis and angiogenesis

Vascular permeability in the retina plays a key role in a wide array of sight-threatening eye diseases such as diabetic retinopathy, and VEGF has been known as a major etiologic factor that increases retinal vascular permeability [28,43,44]. Using a model system for non-proliferative diabetic retinopathy, Liu et al. found that PEDF effectively abated VEGF-induced vascular permeability [43]. PEDF may inhibit the VEGF-induced vascular hyperpermeability via suppression of NADPH oxidase-driven ROS generation [45,46]. Further, we have found that PEDF inhibits AGE-signaling to vascular hyperpermeability in rats [28]. Intravenous administration of AGEs to normal rats not only increased retinal vascular permeability by stimulating VEGF expression, but also decreased retinal PEDF levels [28]. Simultaneous treatments with PEDF inhibited the AGE-elicited VEGF-mediated permeability by down-regulating mRNA levels of p22phox and gp91phox, membrane components of NADPH oxidase and subsequently decreasing retinal levels of an oxidative stress marker, 8-OHdG. PEDF also inhibited the AGE-induced vascular hyperpermeability in ECs by suppressing VEGF expression, which was evaluated by transendothelial electrical resistance. In addition, PEDF decreased ROS generation in AGE-exposed ECs by suppressing NADPH oxidase activity via down-regulation of mRNA levels of p22phox and gp91phox. This led to blockade of the AGE-elicited Ras activation and NF- $\kappa$ B-dependent VEGF gene induction in ECs. These results indicate that the central mechanism for PEDF inhibition of the AGE-signaling to vascular permeability is by suppression of NADPH oxidase-mediated ROS generation and subsequent VEGF expression. Since vitreous level of PEDF was significantly lower in patients with diabetic macular edema (DME) than in non-diabetic patients and diabetic patients without retinopathy, and its level was significantly

lower in patients with hyperfluorescent DME than in those with minimally fluorescent DME [47], PEDF may play a protective role against vascular hyperpermeability in diabetic retinopathy.

AGEs are implicated in the process of vascular inflammation as well [48]. AGEs have been shown to increase leukocyte adhesion to cultured retinal microvascular ECs by inducing intracellular cell adhesion molecule-1 (ICAM-1) expression [49]. This phenomenon is also apparent in non-diabetic mice infused with preformed AGEs, which results in significant leukostasis and blood–retinal barrier dysfunction in these mice. Since retinal VEGF has been found to induce ICAM-1 expression, thus leading to leukostasis and breakdown of blood–retinal barrier *in vivo* [50], the AGE-elicited pro-inflammatory reactions could be partly mediated by VEGF induction. Moreover, we have recently found that AGEs increase monocyte chemoattractant protein-1 (MCP-1) and ICAM-1 expression in microvascular ECs through intracellular ROS generation, thereby inducing T-cell adhesion to ECs [51,52]. Since MCP-1 levels in the vitreous fluids are correlated with the severity of proliferative diabetic retinopathy [53], AGEs would be one of the key pro-inflammatory factors for the progression of diabetic retinopathy. In addition, AGEs not only decrease endothelial nitric oxide synthase (NOS) mRNA levels in ECs, but also reduce NO (nitric oxide) bioavailability by inactivating NO to form peroxynitrite via ROS generation [54]. Reduced synthesis and/or bioavailability of NO may accelerate vascular injury in diabetic retinopathy because NO exerts anti-inflammatory and anti-thrombotic properties *in vivo* [54].

PEDF inhibits the AGE-induced ICAM-1 and MCP-1 induction as well as NO suppression in ECs by blocking the NADPH oxidase-mediated ROS generation [28,52,54–56]. *In vivo*, administration of PEDF or pyridoxal phosphate, an AGE inhibitor decreased retinal levels of 8-OHdG, an oxidative stress marker and subsequently suppressed ICAM-1 expression and retinal leukostasis in diabetic rats [55]. Further, intravenous administration of AGEs to normal rats increased ICAM-1 gene expression and retinal leukostasis, which were blocked by PEDF [55]. PEDF inhibited diabetes- or AGE-induced RAGE overexpression by blocking ROS-mediated NF- $\kappa$ B activation as well [56]. Intravitreal injection of PEDF was also found to reduce vascular hyperpermeability in rat models of diabetes, which was associated with decreased levels of retinal inflammatory factors, including VEGF, MCP-1 and ICAM-1 [57]. Since retinal PEDF expression was decreased under diabetic conditions including diabetic situations [28,58], PEDF



may be a therapeutic target for blocking hyperpermeability and vascular inflammation in diabetic retinopathy as well.

Several researchers have reported that AGEs could augment ADP- or serotonin-induced platelet aggregation via oxidative stress generation [59,60]. Further, AGEs inhibit prostacyclin production and induce plasminogen activator inhibitor-1 (PAI-1) in ECs through an interaction with RAGE [61]. These observations suggest that AGEs have the ability to cause platelet aggregation and fibrin stabilization, which could lead to retinal ischemia and VEGF induction, thereby promoting diabetic retinopathy [62,63]. Since AGEs decrease intracellular cyclic AMP concentrations in ECs and that cyclic AMP agonists such as beraprost sodium and forskolin reduce the AGE-induced PAI-1 production, cyclic AMP elevating agents may also have a therapeutic potential in diabetic retinopathy. In addition, we have found that AGEs directly stimulate growth and tube formation of microvascular ECs, the key steps of angiogenesis, through the interaction with RAGE [64–66]. Our research findings have suggested that AGE–RAGE interaction could increase VEGF gene expression in microvascular ECs by NADPH oxidase-mediated ROS generation and subsequent NF- $\kappa$ B activation via Ras-MAPK pathway [64–66].

ARBs and angiotensin-converting enzyme inhibitors (ACEIs) may block the formation of reactive carbonyl precursors for AGEs *in vitro* by chelating transition metals and inhibiting hydroxyl radicals, at both pre- and post-Amadori steps [67]. In addition, we have found that an ARB, olmesartan inhibits the AGE-evoked inflammatory and angiogenic reactions in ECs by suppressing RAGE expression via its anti-oxidative properties [68]. These findings suggest that RAS inhibitors may exert beneficial effects on diabetic retinopathy partly via its inhibitory properties on the AGE–RAGE axis.

### 3. Role of AGEs, RAS and PEDF in diabetic nephropathy

#### 3.1. Mesangial cell loss and dysfunction

As the case in pericytes, AGEs induce apoptotic cell death and VEGF expression in human cultured mesangial cells [69,70]. Mesangial cells occupy a central anatomical position in the glomerulus, playing crucial roles in maintaining structure and function of glomerular capillary tufts [69,70]. They actually provide structural support for capillary loops and modulate glomerular filtration by its smooth muscle activity [70]. Therefore, it is conceivable that the AGE-induced mesangial apoptosis and dysfunction may contribute in part to glomerular hyperfiltration, an early renal dysfunction in diabetes. Several experimental and clinical studies support the pathological role for VEGF in diabetic nephropathy. Indeed, antibodies raised against VEGF have been reported to improve hyperfiltration and albuminuria in streptozotocin-induced diabetic rats [71]. Inhibition of VEGF also prevents glomerular hypertrophy in Zucker diabetic fatty rats, a model animal of type 2 diabetes with obesity [72]. Further, urinary VEGF levels are positively correlated with urinary albumin to creatinine ratio, and inversely associated with creatinine clearance in type 2 diabetic patients [73]. These observations suggest that VEGF overproduction elicited by AGEs may be involved in hyperpermeability and albuminuria at early phase of diabetic nephropathy.

Moreover, we have found that AGEs stimulate MCP-1 expression in mesangial cells as well [69,70]. Increased MCP-1 expression associated with monocyte infiltration in mesangial areas has been observed at early phase of diabetic nephropathy [74]. Plasma MCP-1 was positively correlated with urinary albumin excretion rate in type 1 diabetic patients as well [75]. Therefore, AGE accumulation in the glomerulus could be implicated in the initiation of diabetic nephropathy via MCP-1 induction. Since we have recently found that glucagon-like peptide-1 inhibits AGE-induced vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in ECs and mesangial cells by suppressing RAGE expression via cyclic AMP elevation [76], cyclic AMP may also block the AGE-signaling pathways in mesangial cells.

#### 3.2. Glomerulosclerosis and tubulointerstitial fibrosis

AGEs stimulate insulin-like growth factor-I, -II, platelet-derived growth factor (PDGF) and transforming growth factor- $\beta$  (TGF- $\beta$ ) in mesangial cells, which in turn mediate production of type IV collagen, laminin and fibronectin [70,77,78]. AGEs induce TGF- $\beta$  overexpression in both podocytes and proximal tubular cells as well [70,78]. Recently, Ziyadeh et al. reported that long-term treatment of type 2 diabetic model mice with blocking antibodies raised against TGF- $\beta$  suppressed excess matrix gene expression, glomerulosclerosis, and prevented the development of renal insufficiency [79]. These observations suggest that the AGE-induced TGF- $\beta$  expression plays an important role in the pathogenesis of glomerulosclerosis and tubulointerstitial fibrosis in diabetic nephropathy.

AGE formation on extracellular matrix proteins alters both matrix–matrix and cell–matrix interactions, which is also involved in the pathogenesis of diabetic glomerulosclerosis. For example, non-enzymatic glycation of type IV collagen and laminin reduce their ability to interact with negatively charged proteoglycans, increasing vascular permeability to albumin [70]. Furthermore, AGE formation on various types of matrix proteins impairs their degradation by matrix metalloproteinases, contributing to basement membrane thickening and mesangial expansion, hallmarks of diabetic nephropathy [54]. AGEs including glycoxidation or lipoxidation products such as carboxymethyllysine (CML), pentosidine, malondialdehyde-lysine accumulate in the expanded mesangial matrix and thickened glomerular basement membranes of early diabetic nephropathy, and in nodular lesions of advanced disease, thus further suggesting the active involvement of AGEs for advanced diabetic nephropathy [80].

*In vivo*, administration of AGE-albumin to normal healthy mice for 4 weeks induces glomerular hypertrophy with overexpression of type IV collagen, laminin B1 and TGF- $\beta$  genes [81]. Chronic infusion of AGE-albumin to otherwise healthy rats leads to focal glomerulosclerosis, mesangial expansion, and albuminuria [82]. Further, diabetic RAGE-overexpressing mice have been found to show progressive glomerulosclerosis with renal dysfunction, compared with diabetic littermates lacking the RAGE transgene [83]. AGEs and RAGE were present to enhanced degrees in the diabetic kidney, and blockade of the AGE–RAGE interaction decreased podocyte VEGF expression and albuminuria, which was associated with decreased numbers of inflammatory cells to, and reduced TGF- $\beta$  expression, in the glomerulus [84]. In addition, diabetic homozygous RAGE null mice failed to develop significantly increased mesangial matrix expansion or thickening of the glomerular basement membrane [84]. Deletion of RAGE is also reported to prevent diabetic nephropathy in the OVE26 type 1 mouse, a model of progressive glomerulosclerosis and decline of renal function [85]. Taken together, these findings suggest that activation of AGE–RAGE system contributes to expression of VEGF and enhanced attraction/activation of inflammatory cells in the diabetic glomerulus, thereby setting the stage for mesangial activation and TGF- $\beta$  production; processes which converge to cause albuminuria and glomerulosclerosis.

#### 3.3. Crosstalk of the AGE–RAGE system with the RAS

Since Ang II increases intracellular ROS generation in renal cells, it may stimulate the production of AGEs and further augment the AGE–RAGE system in diabetic kidney [86,87]. There is accumulating *in vitro*- and *in vivo*-evidence to suggest the pathophysiological crosstalk between the RAS and AGE–RAGE axis in diabetic nephropathy. Indeed, AGEs activate mesangial TGF- $\beta$ –Smad system in cultured mesangial cells via autocrine production of angiotensin II and subsequent activation of type 1 receptor, which could probably lead to mesangial cell hypertrophy and glomerular sclerosis in diabetic nephropathy [77]. Further, we have found that an ARB, irbesartan blocks the AGE–

RAGE-induced ROS generation, apoptosis, MCP-1, PAI-1 and TGF- $\beta$  overexpression in proximal tubular cells, thus protecting against tubulointerstitial inflammation, fibrosis and atrophy in diabetic nephropathy [88] (Fig. 2). In addition, irbesartan was recently found to prevent the AGE-induced podocyte apoptosis and injury as well; anti-apoptotic effect of irbesartan on AGE-exposed podocytes was stronger than that of valsartan (Fig. 3). Since there is accumulating evidence that podocyte apoptosis and injury are implicated in the progression of diabetic nephropathy [89], blockade of the crosstalk between the AGE–RAGE system and the RAS by RAS inhibitors such as irbesartan is a therapeutic target for preventing diabetic nephropathy.

In animal models, Forbes et al. have reported that an ACEI, ramipril decreases circulating and renal tissue levels of AGEs in experimental diabetic nephropathy [86]. Candesartan, an ARB, reduces AGEs accumulation and subsequent albuminuria by down-regulating the NADPH oxidase p47phox component and inducible NOS expression and by attenuating RAGE expression in type 2 diabetic KK/Ta mouse kidneys [90]. Thomas et al. reported that valsartan, other ARB reduced renal levels of AGEs in AGE-injected animals, whereas Ang II infusion accelerated the formation and accumulation of AGEs in both glomeruli and renal tubules in their models [87]. In addition, we have found that administration of olmesartan medoxomil inhibits the increase of systolic and diastolic blood pressure and urinary *N*-acetyl-beta-D-glucosaminidase activity and prevent glomerulosclerosis in exogenously AGE-injected rats [91]. In humans, an ACEI, ramipril treatment has been shown to result in a mild decline of fluorescent non-CML-AGEs and malondialdehyde concentrations in non-diabetic nephropathy patients [92]. In type 2 diabetic subjects, a low-dose of valsartan treatment was reported to decrease serum AGE levels in a blood pressure-independent manner [93]. These observations suggest that there could exist a pathophysiological crosstalk between the AGE–RAGE system and the RAS in diabetic nephropathy. Blood pressure-lowering independent beneficial effects of RAS inhibitors on diabetic nephropathy [94] could be ascribed at least in part to its inhibitory effects of the AGE–RAGE–oxidative stress system.

### 3.4. Role of peroxisome proliferator-activated receptor- $\gamma$ (PPAR $\gamma$ )

Several papers have shown that PPAR $\gamma$  agonists block the deleterious effects of AGEs and exert beneficial actions on diabetic nephropathy [95,96]. Indeed, activation of PPAR $\gamma$  by rosiglitazone inhibited AGE-induced inducible NOS expression, nitrite release,

fibronectin and type IV collagen production by mesangial cells [95,96]. Rosiglitazone also attenuated the AGE-induced interleukin-8 and soluble ICAM-1 generation by proximal tubular epithelial cells through the suppression of signal transducer and activator of transcription [97]. Further, rosiglitazone was reported to inhibit renal extracellular matrix accumulation, fibronectin, type IV collagen and PAI-1 production and subsequently reduce proteinuria in AGE-injected rats [97].

Suppression of RAGE expression may be a molecular target of PPAR $\gamma$  agonists [19,97–106]. Marx et al. reported that stimulation of human ECs with PPAR $\gamma$  agonists such as rosiglitazone and pioglitazone decreased basal as well as tumor necrosis factor- $\alpha$ -induced RAGE expression via suppression of NF- $\kappa$ B activation. They also showed that PPAR $\gamma$  agonists decreased AGE-induced MCP-1 expression in ECs [98]. Further, we have found that telmisartan, an ARB, down-regulates RAGE expression and suppresses its downstream signalings in various cell types through its unique PPAR $\gamma$ -modulating ability [100–104]. Indeed, telmisartan was found to reduce RAGE mRNA levels and subsequently inhibit superoxide generation as well as MCP-1 expression in mesangial cells, all of which were prevented by GW9662, an inhibitor of PPAR $\gamma$  [102]. In addition, we have recently found that nifedipine, but not amlodipine, a control calcium channel blocker, decreased RAGE mRNA levels and subsequently reduced ROS generation, and VCAM-1 and MCP-1 expression in AGE-exposed mesangial cells, all of which were blocked by the simultaneous treatment of GW9662 [106]. Although nifedipine did not affect expression levels of PPAR $\gamma$ , it increased the PPAR $\gamma$  transcriptional activity in mesangial cells. Taken together, these observations provide unique beneficial aspect of telmisartan and nifedipine on diabetic nephropathy; it could work as an anti-inflammatory agent against AGEs by suppressing RAGE expression in cultured mesangial cells via PPAR $\gamma$  activation.

There are a couple of papers to suggest the protective effects of PEDF against diabetic nephropathy. PEDF was decreased at both mRNA and protein levels in the kidney of diabetic rats, whereas TGF- $\beta$  and fibronectin levels were increased in the same diabetic kidneys [107]. *In vitro*-studies showed that high concentrations of glucose significantly decreased PEDF secretion in human mesangial cells, thus suggesting that hyperglycemia is a direct cause of the PEDF decrease in the kidney. Further, PEDF blocked the high-glucose-induced overexpression of TGF- $\beta$ , a major pathogenic factor in diabetic nephropathy, and fibronectin in mesangial cells [107]. Therefore,





Fig. 2. Role of AGE–RAGE axis and RAS in tubular injury in diabetic nephropathy.



**Fig. 3.** Effects of irbesartan on ROS generation (A) and apoptotic cell death (B) in immortalized mouse podocytes [126]. Differentiated podocytes were treated with 100 g/ml AGE-bovine serum albumin (BSA) (AGEs) or non-glycated BSA (BSA) in the presence or absence of 1 μM irbesartan (a generous gift from Daiinippon Sumitomo Pharma, Tokyo, Japan) or valsartan (Toronto Research Chemicals Inc., Ontario, Canada) for 16 h (A) or 24 h (B). (A) Then the cells were incubated with phenol red free Dulbecco's Modified Eagle Medium containing 3 μM dihydroethidium (DHE) (Molecular Probes Inc., Eugene, OR, USA) as described previously [109]. Intensity of DHE staining in 5 different field of each sample was analyzed by microcomputer-assisted image]. (B) Apoptotic cells were measured by flow cytometry as described previously [109]. For every histogram, 5000 podocytes were counted to evaluate the percentage of apoptotic cells. \* and \*\*,  $p < 0.05$  and  $p < 0.01$  compared to the value with AGEs alone, respectively.

decreased expression of PEDF in diabetic kidneys may contribute to extracellular matrix overproduction and the development of diabetic nephropathy. *In vivo*, overexpression of PEDF was found to alleviate microalbuminuria, to prevent the expression of two major fibrogenic factors, TGF-β and connective tissue growth factor (CTGF), and to significantly reduce the production of an extracellular matrix protein in the diabetic kidney [108]. These findings suggest that PEDF functions as an endogenous anti-TGF-β and anti-fibrogenic factor in the kidney. A therapeutic potential of PEDF in diabetic nephropathy is supported by its down-regulation in diabetes; its prevention of the overexpression of TGF-β, CTGF, and extracellular matrix proteins in diabetic kidney; and its amelioration. Moreover, we have recently found that PEDF inhibits the AGE-induced RAGE gene expression and reduced ROS generation, inflammatory and fibrogenic gene expression (MCP-1, TGF-β, fibronectin and type IV collagen gene expression) in cultured human proximal tubular cells [109]. PEDF administration inhibited oxidative stress generation and RAGE, MCP-1 and TGF-β gene induction in diabetic kidneys as well [109]. Given that RAGE is a cell receptor for AGEs that mainly mediates the biological effects of these macroproteins and that ROS generation works as a second messenger of RAGE-downstream pathways for MCP-1 and TGF-β gene induction [1,17,88,106], the results suggest that RAGE gene suppression in tubular cells would be a central mechanism by which PEDF inhibited inflammatory and fibrogenic reactions in early phase of diabetic nephropathy. Since PEDF activates PPARγ signaling in variety of cells [110,111], PEDF may reduce RAGE gene expression in diabetic kidney via PPARγ.

### 3.5. Clinical trial

Double-blinded, placebo-controlled, randomized clinical trials of aminoguanidine (Pimagedine®), a prototype therapeutic agent for the prevention of AGE formation (ACTION; A Clinical Trial In Overt Nephropathy), were designed to evaluate the safety and efficacy of aminoguanidine in retarding the rate of progression of renal disease in patients with overt diabetic nephropathy. Pimagedine® therapy reduced the 24-h total urinary proteinuria and prevented the decrease in glomerular filtration rate and the progression of diabetic retinopathy in patients with type 1 diabetes [112]. However, the effects of Pimagedine® on serum creatinine doubling were found not to be significant; serum creatinine doubled in 26% of the placebo-treated patients and in 20% of those who received Pimagedine ( $p = 0.099$ ). This study is noteworthy in providing the first clinical proof of the concept that inhibiting AGE formation can result in a clinically

important attenuation of the serious complication of diabetes. Reported side effects of aminoguanidine in clinical therapy were gastrointestinal disturbance, abnormalities in liver function tests, flu-like symptoms, and a rare vasculitis [112]. Further clinical trials of aminoguanidine were terminated due to safety concerns.

### 4. Role of AGEs and RAS in diabetic macroangiopathy

AGEs formed on the extracellular matrix result in decreased elasticity of vasculatures, and quench NO, which could mediate defective endothelium-dependent vasodilatation in diabetes [113]. Indeed, increased oxidative stress generation induced by AGEs inactivates NO to form peroxynitrite. AGE modification of low-density lipoprotein (LDL) exhibits impaired plasma clearance and contributes significantly to increased LDL *in vivo*, thus being involved in atherosclerosis [114]. Binding of AGEs to RAGE results in generation of intracellular ROS generation and subsequent activation of the redox-sensitive transcription factor NF-κB in vascular wall cells, which promotes the expression of a variety of atherosclerosis-related genes, including ICAM-1, VCAM-1, MCP-1, PAI-1, tissue factor, VEGF, and RAGE [1,17].

Bone marrow-derived circulating endothelial progenitor cells (EPCs) are critical to vascular repair [115]. Diabetes is associated with endothelial dysfunction, decreased EPC function and mobilization, which could contribute to accelerated atherosclerosis and increased risk for CVD in diabetic patients [115]. AGEs enhance apoptosis and suppress migration and tube formation of late EPCs through the interaction with RAGE via down-regulation of Akt and cyclooxygenase-2 [116]. AGEs have also been shown to cause a reduction of length growth and EPC incorporation into the sprouts in association with RAGE overexpression and p38 mitogen-activated protein kinase (MAPK) activation [117]. Furthermore, AGE-modification of vascular substrates impair vascular repair by inhibiting EPC adhesion, spreading and migration via glycation of Arg-Gly-Asp (RGD) motif of fibronectin [118]. In addition, C-reactive protein (CRP) has been found to increase oxidative stress generation, alter anti-oxidant defenses, and subsequently induces apoptosis of EPCs via RAGE induction [119]. These observations suggest that AGE-RAGE axis affects collateral artery formation after myocardial ischemia directly and indirectly by impairing vascular repair and inactivating NO, a mediator of angiogenic signal of VEGF [120]. Recently, skin autofluorescence, an established noninvasive measure of AGE accumulation, but not serum pentosidine, was independently associated with low circulating EPCs in subjects with ESRD [121].



Further, AGEs have the ability to induce osteoblastic differentiation of microvascular pericytes, which would contribute to the development of vascular calcification in accelerated atherosclerosis in diabetes as well [122]. The interaction of the RAS and the AGE–RAGE system in the development of and progression of diabetic vascular complication has also been proposed. The AGE–RAGE interaction augments angiotensin II-induced smooth muscle cell proliferation and activation, thus being involved in accelerated atherosclerosis in diabetes [123].

Smooth muscle cell proliferation, migration, and neointimal expansion upon arterial injury were strikingly suppressed in homozygous RAGE null mice compared with those observed in wild-type littermates [124]. These data highlight key roles for RAGE in modulating smooth muscle cell properties after injury and suggest that RAGE is a logical target for suppression of untoward neointimal expansion consequent to arterial injury. Diabetic RAGE(–/–)/apoE(–/–) mice had significantly reduced atherosclerotic plaque area, which is associated with attenuation of leukocyte recruitment, decreased expression of pro-inflammatory mediators, reduced oxidative stress and AGE accumulation [125].

## 5. Conclusion

Inhibition of the AGE formation and blockade of the AGE–RAGE system and its crosstalk with the RAS may become novel therapeutic strategies in vascular complications of diabetes.

## Acknowledgments

This work was supported in part by Grants of Collaboration with Venture Companies Project from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

## References

- [1] S. Yamagishi, T. Imaizumi, Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy, *Curr. Pharm. Des.* 11 (2005) 2279–2299.
- [2] M. Brownlee, Biochemistry and molecular cell biology of diabetic complications, *Nature* 414 (2001) 813–820.
- [3] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, *N. Engl. J. Med.* 329 (1993) 977–986.
- [4] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, *Lancet* 352 (1998) 837–853.
- [5] Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, *N. Engl. J. Med.* 342 (2000) 381–389.
- [6] Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study, *JAMA* 290 (2003) 2159–2167.
- [7] D.M. Nathan, J. Lachin, P. Cleary, T. Orchard, D.J. Brillion, J.Y. Backlund, D.H. O'Leary, S. Genuth, Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus, *N. Engl. J. Med.* 348 (2003) 2294–2303.
- [8] D.M. Nathan, P.A. Cleary, J.Y. Backlund, S.M. Genuth, J.M. Lachin, T.J. Orchard, P. Raskin, B. Zinman, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, *N. Engl. J. Med.* 353 (2005) 2643–2653.
- [9] R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, H.A. Neil, 10-year follow-up of intensive glucose control in type 2 diabetes, *N. Engl. J. Med.* 359 (2008) 1577–1589.
- [10] M. Brownlee, A. Cerami, H. Vlassara, Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications, *N. Engl. J. Med.* 318 (1988) 1315–1321.
- [11] H. Vlassara, M.R. Palace, Diabetes and advanced glycation endproducts, *J. Intern. Med.* 251 (2002) 87–101.
- [12] M. Takeuchi, S. Yamagishi, Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease, *J. Alzheimers Dis.* 16 (2009) 845–858.
- [13] D.G. Dyer, J.A. Blackledge, S.R. Thorpe, J.W. Baynes, Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification glucose other carbohydrates as possible precursors pentosidine vivo, *J. Biol. Chem.* 266 (1991) 11654–11660.

- [14] D. Stern, S.D. Yan, S.F. Yan, A.M. Schmidt, Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings, *Adv. Drug Deliv. Rev.* 54 (2002) 1615–1625.
- [15] A. Bierhaus, M.A. Hofmann, R. Ziegler, P.P. Nawroth, AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus: I. The AGE concept, *Cardiovasc. Res.* 37 (1998) 586–600.
- [16] S. Yamagishi, K. Nakamura, T. Matsui, S. Ueda, K. Fukami, S. Okuda, Agents that block advanced glycation end product (AGE)–RAGE (receptor for AGEs)–oxidative stress system: a novel therapeutic strategy for diabetic vascular complications, *Expert Opin. Invest. Drugs* 17 (2008) 983–996.
- [17] S. Yamagishi, K. Nakamura, T. Matsui, Y. Noda, T. Imaizumi, Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication, *Curr. Pharm. Des.* 14 (2008) 487–495.
- [18] K. Takenaka, S. Yamagishi, T. Matsui, K. Nakamura, T. Imaizumi, Role of advanced glycation end products (AGEs) in thrombotic abnormalities in diabetes, *Curr. Neurovasc. Res.* 3 (2006) 73–77.
- [19] S. Yamagishi, K. Nakamura, T. Matsui, Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders, *Curr. Mol. Med.* 7 (2007) 463–469.
- [20] R.N. Frank, On the pathogenesis of diabetic retinopathy. A 1990 update, *Ophthalmology* 98 (1991) 586–593.
- [21] A.W. Stitt, Y.M. Li, T.A. Gardiner, R. Bucala, D.B. Archer, H. Vlassara, Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats, *Am. J. Pathol.* 150 (1997) 523–531.
- [22] S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, K. Koga, N. Sasaki, H. Yamamoto, M. Takeuchi, Z. Makita, Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes, *Biochem. Biophys. Res. Commun.* 290 (2002) 973–978.
- [23] S. Yamagishi, Y. Inagaki, S. Amano, T. Okamoto, M. Takeuchi, Z. Makita, Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties, *Biochem. Biophys. Res. Commun.* 296 (2002) 877–882.
- [24] S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, M. Takeuchi, Z. Makita, Beraprost sodium, a prostaglandin I<sub>2</sub> analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes, *Mol. Med.* 8 (2002) 546–550.
- [25] L. Ottonello, M.P. Morone, P. Dapino, F. Dallegrì, Tumor necrosis factor- $\alpha$ -induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents, *Br. J. Haematol.* 91 (1995) 566–570.
- [26] L.P. Aiello, R.L. Avery, P.G. Arrigg, B.A. Keyt, H.D. Jampel, S.T. Shah, L.R. Pasquale, H. Thieme, M.A. Iwamoto, J.E. Park, et al., Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders, *N. Engl. J. Med.* 331 (1994) 1480–1487.
- [27] T. Murata, T. Ishibashi, A. Khalil, Y. Hata, H. Yoshikawa, H. Inomata, Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels, *Ophthalmic Res.* 27 (1995) 48–52.
- [28] S. Yamagishi, K. Nakamura, T. Matsui, Y. Inagaki, K. Takenaka, Y. Jinnouchi, Y. Yoshida, T. Matsuura, I. Narama, Y. Motomiya, M. Takeuchi, H. Inoue, A. Yoshimura, R. Bucala, T. Imaizumi, Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression, *J. Biol. Chem.* 281 (2006) 20213–20220.
- [29] S. Anderson, Role of local and systemic angiotensin in diabetic renal disease, *Kidney Int. Suppl.* 63 (1997) S107–S110.
- [30] S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, H. Inoue, M. Takeuchi, H. Choei, N. Sasaki, S. Kikuchi, Angiotensin II type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation, *Drugs Exp. Clin. Res.* 29 (2003) 75–80.
- [31] S. Amano, S. Yamagishi, Y. Inagaki, T. Okamoto, Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation, *Int. J. Tissue React.* 25 (2003) 51–55.
- [32] S. Yamagishi, M. Takeuchi, T. Matsui, K. Nakamura, T. Imaizumi, H. Inoue, Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression, *FEBS Lett.* 579 (2005) 4265–4270.
- [33] J. Tombran-Tink, C.J. Barnstable, PEDF: a multifaceted neurotrophic factor, *Nat. Rev. Neurosci.* 4 (2003) 628–636.
- [34] S.P. Becerra, Focus on molecules: pigment epithelium-derived factor (PEDF)Exp. Eye Res. 82 (2006) 739–740.
- [35] E.T. Ek, R.C. Dass, P.F. Choong, PEDF: a potential molecular therapeutic target with multiple anti-cancer activities, *Trends Mol. Med.* 12 (2006) 497–502.
- [36] R. Abe, Y. Fujita, S. Yamagishi, Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma, *Mini Rev Med Chem* 7 (2007) 649–661.
- [37] S. Yamagishi, T. Matsui, K. Nakamura, S. Ueda, Y. Noda, T. Imaizumi, Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications, *Curr. Drug Targets* 9 (2008) 1025–1029.
- [38] S. Yamagishi, K. Nakamura, K. Takenaka, T. Matsui, Y. Jinnouchi, T. Imaizumi, Pigment epithelium-derived factor (PEDF) promotes growth of pericytes through autocrine production of platelet-derived growth factor-B, *Microvasc. Res.* 69 (2005) 128–134.
- [39] S. Yamagishi, T. Matsui, K. Nakamura, H. Inoue, Pigment epithelium-derived factor is a pericyte mitogen secreted by microvascular endothelial cells: possible

- participation of angiotensin II-elicited PEDF downregulation in diabetic retinopathy, *Int. J. Tissue React.* 27 (2005) 197–202.
- [40] H.P. Hammes, S. Martin, K. Federlin, K. Geisen, M. Brownlee, Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy, *Proc. Natl Acad. Sci. U.S.A.* 88 (1991) 11555–11558.
- [41] A. Stitt, T.A. Gardiner, N.L. Alderson, P. Canning, N. Frizzell, N. Duffy, C. Boyle, A.S. Januszewski, M. Chachich, J.W. Baynes, S.R. Thorpe, The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes, *Diabetes* 51 (2002) 2826–2832.
- [42] R.A. Kowluru, S. Odenbach, Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats, *Diabetes* 53 (2004) 3233–3238.
- [43] H. Liu, J.G. Ren, W.L. Cooper, C.E. Hawkins, M.R. Cowan, P.Y. Tong, Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site, *Proc. Natl Acad. Sci. U.S.A.* 101 (2004) 6605–6610.
- [44] S.X. Zhang, J.J. Wang, G. Gao, K. Parke, J.X. Ma, Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF–VEGF receptor 2 binding in diabetic retinopathy, *J. Mol. Endocrinol.* 37 (2006) 1–12.
- [45] S. Yamagishi, R. Abe, Y. Jinnouchi, T. Matsui, T. Imaizumi, H. Inoue, Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo, *J. Int. Med. Res.* 35 (2007) 896–899.
- [46] Y. Jinnouchi, S. Yamagishi, T. Matsui, K. Takenaka, Y. Yoshida, K. Nakamura, S. Ueda, T. Imaizumi, Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice, *Brain Res.* 1167 (2007) 92–100.
- [47] H. Funatsu, H. Yamashita, S. Nakamura, T. Mimura, S. Eguchi, H. Noma, S. Hori, Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema, *Ophthalmology* 113 (2006) 294–301.
- [48] S. Schroder, W. Palinski, G.W. Schmid-Schonbein, Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy, *Am. J. Pathol.* 139 (1991) 81–100.
- [49] T.C. Moore, J.E. Moore, Y. Kaji, N. Frizzell, T. Usui, V. Poulaki, I.L. Campbell, A.W. Stitt, T.A. Gardiner, D.B. Archer, A.P. Adamis, The role of advanced glycation end products in retinal microvascular leukostasis, *Invest Ophthalmol Vis Sci* 44 (2003) 4457–4464.
- [50] M. Lu, V.L. Perez, N. Ma, K. Miyamoto, H.B. Peng, J.K. Liao, A.P. Adamis, VEGF increases retinal vascular ICAM-1 expression in vivo, *Invest Ophthalmol Vis Sci* 40 (1999) 1808–1812.
- [51] S. Yamagishi, T. Matsui, K. Nakamura, H. Inoue, M. Takeuchi, S. Ueda, S. Okuda, T. Imaizumi, Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species, *Ophthalmic Res.* 40 (2008) 10–15.
- [52] Y. Inagaki, S. Yamagishi, T. Okamoto, M. Takeuchi, S. Amano, Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation, *Diabetologia* 46 (2003) 284–287.
- [53] Y. Mitamura, S. Takeuchi, A. Matsuda, Y. Tagawa, Y. Mizue, J. Nishihira, Monocyte chemoattractant protein-1 in the vitreous of patients with proliferative diabetic retinopathy, *Ophthalmologica* 215 (2001) 415–418.
- [54] S. Yamagishi, S. Ueda, T. Matsui, K. Nakamura, T. Imaizumi, M. Takeuchi, S. Okuda, Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties, *Protein Pept. Lett.* 14 (2007) 832–835.
- [55] S. Yamagishi, T. Matsui, K. Nakamura, M. Takeuchi, T. Imaizumi, Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis, *Microvasc. Res.* 72 (2006) 86–90.
- [56] S. Yamagishi, T. Matsui, K. Nakamura, T. Yoshida, M. Takeuchi, H. Inoue, Y. Yoshida, T. Imaizumi, Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats, *Ophthalmic Res.* 39 (2007) 92–97.
- [57] S.X. Zhang, J.J. Wang, G. Gao, C. Shao, R. Mott, J.X. Ma, Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor, *FASEB J.* 20 (2006) 323–325.
- [58] S. Yamagishi, T. Matsui, H. Inoue, Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells, *Drugs Exp. Clin. Res.* 31 (2005) 227–232.
- [59] M. Hangaishi, J. Taguchi, T. Miyata, Y. Ikari, M. Togo, Y. Hashimoto, T. Watanabe, S. Kimura, K. Kurokawa, M. Ohno, Increased aggregation of human platelets produced by advanced glycation end products in vitro, *Biochem. Biophys. Res. Commun.* 248 (1998) 285–292.
- [60] M. Zoltowska, E. Delvin, E. Ziv, N. Peretti, M. Chartre, E. Levy, Impact of in vivo glycation of LDL on platelet aggregation and monocyte chemotaxis in diabetic psammomys obesus, *Lipids* 39 (2004) 81–85.
- [61] S. Yamagishi, H. Fujimori, H. Yonekura, Y. Yamamoto, H. Yamamoto, Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells, *Diabetologia* 41 (1998) 1435–1441.
- [62] M. Nomura, S. Yamagishi, S. Harada, Y. Hayashi, T. Yamashima, J. Yamashita, H. Yamamoto, Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes, *J. Biol. Chem.* 270 (1995) 28316–28324.
- [63] S. Yamagishi, T. Kawakami, H. Fujimori, H. Yonekura, N. Tanaka, Y. Yamamoto, H. Urayama, Y. Watanabe, H. Yamamoto, Insulin stimulates the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor, *Microvasc. Res.* 57 (1999) 329–339.
- [64] S. Yamagishi, H. Yonekura, Y. Yamamoto, K. Katsuno, F. Sato, I. Mita, H. Ooka, N. Satozawa, T. Kawakami, M. Nomura, H. Yamamoto, Advanced glycation end products-driven angiogenesis in vitro. Induction growth tube formation human microvascular endothelial cells autocrine vascular endothelial growth factor, *J Biol Chem* 272 (1997) 8723–8730.
- [65] T. Okamoto, S. Yamagishi, Y. Inagaki, S. Amano, K. Koga, R. Abe, M. Takeuchi, S. Ohno, A. Yoshimura, Z. Makita, Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin, *FASEB J.* 16 (2002) 1928–1930.
- [66] T. Okamoto, S. Yamagishi, Y. Inagaki, S. Amano, M. Takeuchi, S. Kikuchi, S. Ohno, A. Yoshimura, Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro, *Biochem. Biophys. Res. Commun.* 297 (2002) 419–424.
- [67] T. Miyata, C. van Ypersele, Y. de Strihou, K. Ueda, R. Ichimori, H. Inagi, N. Onogi, M. Ishikawa, K. Kurokawa Nangaku, Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms, *J. Am. Soc. Nephrol.* 13 (2002) 2478–2487.
- [68] S. Yamagishi, T. Matsui, K. Nakamura, H. Inoue, M. Takeuchi, S. Ueda, K. Fukami, S. Okuda, T. Imaizumi, Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression, *Microvasc. Res.* 75 (2008) 130–134.
- [69] S. Yamagishi, Y. Inagaki, T. Okamoto, S. Amano, K. Koga, M. Takeuchi, Z. Makita, Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells, *J. Biol. Chem.* 277 (2002) 20309–20315.
- [70] S. Yamagishi, K. Fukami, S. Ueda, S. Okuda, Molecular mechanisms of diabetic nephropathy and its therapeutic intervention, *Curr. Drug Targets* 8 (2007) 952–959.
- [71] A.S. de Vriese, R.G. Tilton, M. Elger, C.C. Stephan, W. Kriz, N.H. Lameire, Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes, *J. Am. Soc. Nephrol.* 12 (2001) 993–1000.
- [72] B.F. Schrijvers, A. Flyvbjerg, R.G. Tilton, N.H. Lameire, A.S. De Vriese, A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat, *Nephrol. Dial. Transplant.* 21 (2006) 324–329.
- [73] N.H. Kim, J.H. Oh, J.A. Seo, K.W. Lee, S.G. Kim, K.M. Choi, S.H. Baik, D.S. Choi, Y.S. Kang, S.Y. Han, K.H. Han, Y.H. Ji, D.R. Cha, Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy, *Kidney Int.* 67 (2005) 167–177.
- [74] N. Banba, T. Nakamura, M. Matsumura, H. Kuroda, Y. Hattori, K. Kasai, Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy, *Kidney Int.* 58 (2000) 684–690.
- [75] F. Chiarelli, F. Cipollone, A. Mohn, M. Marini, A. Iezzi, M. Fazio, S. Tumini, D. De Cesare, M. Pomilio, S.D. Pierdomenico, M. Di Gioacchino, F. Cuccurullo, A. Mezzetti, Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes, *Diabetes Care* 25 (2002) 1829–1834.
- [76] Ishibashi, Y., Matsui, T., Takeuchi, M., Yamagishi, S., Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression, *Biochem Biophys Res Commun* 391 1405–1408.
- [77] K. Fukami, S. Ueda, S. Yamagishi, S. Kato, Y. Inagaki, M. Takeuchi, Y. Motomiya, R. Bucala, S. Iida, K. Tamaki, T. Imaizumi, M.E. Cooper, S. Okuda, AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction, *Kidney Int.* 66 (2004) 2137–2147.
- [78] S. Yamagishi, Y. Inagaki, T. Okamoto, S. Amano, K. Koga, M. Takeuchi, Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells, *Kidney Int.* 63 (2003) 464–473.
- [79] F.N. Ziyadeh, B.B. Hoffman, D.C. Han, M.C. Iglesias-De La Cruz, S.W. Hong, M. Isono, S. Chen, T.A. McGowan, K. Sharma, Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice, *Proc. Natl Acad. Sci. U.S.A.* 97 (2000) 8015–8020.
- [80] D. Suzuki, T. Miyata, N. Saotome, K. Horie, R. Inagi, Y. Yasuda, K. Uchida, Y. Izuhara, M. Yagame, H. Sakai, K. Kurokawa, Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions, *J. Am. Soc. Nephrol.* 10 (1999) 822–832.
- [81] C.W. Yang, H. Vlassara, E.P. Peten, C.J. He, G.E. Striker, L.J. Striker, Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease, *Proc. Natl Acad. Sci. U.S.A.* 91 (1994) 9436–9440.
- [82] H. Vlassara, L.J. Striker, S. Teichberg, H. Fuh, Y.M. Li, M. Steffes, Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats, *Proc. Natl Acad. Sci. U.S.A.* 91 (1994) 11704–11708.
- [83] Y. Yamamoto, I. Kato, T. Doi, H. Yonekura, S. Ohashi, M. Takeuchi, T. Watanabe, S. Yamagishi, S. Sakurai, S. Takasawa, H. Okamoto, H. Yamamoto, Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice, *J. Clin. Invest.* 108 (2001) 261–268.
- [84] T.M. Wendt, N. Tanji, J. Guo, T.R. Kislinger, W. Qu, Y. Lu, L.G. Bucciarelli, L.L. Rong, B. Moser, G.S. Markowitz, G. Stein, A. Bierhaus, B. Liliensiek, B. Arnold, P.P. Nawroth, D.M. Stern, V.D. D'Agati, A.M. Schmidt, RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy, *Am. J. Pathol.* 162 (2003) 1123–1137.



- [85] N. Reiniger, K. Lau, D. McCalla, B. Eby, B. Cheng, Y. Lu, W. Qu, N. Quadri, R. Ananthakrishnan, M. Furmansky, R. Rosario, F. Song, V. Rai, A. Weinberg, R. Friedman, R. Ramasamy, V. D'Agati, A.M. Schmidt, Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse, *Diabetes* 59 (2010) 2043–2054.
- [86] J.M. Forbes, M.E. Cooper, V. Thallas, W.C. Burns, M.C. Thomas, G.C. Brammar, F. Lee, S.L. Grant, L.M. Burrell, G. Jerums, T.M. Osicka, Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy, *Diabetes* 51 (2002) 3274–3282.
- [87] M.C. Thomas, C. Tikellis, W.M. Burns, K. Bialkowski, Z. Cao, M.T. Coughlan, K. Jandeleit-Dahm, M.E. Cooper, J.M. Forbes, Interactions between renin angiotensin system and advanced glycation in the kidney, *J. Am. Soc. Nephrol.* 16 (2005) 2976–2984.
- [88] T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, S. Okuda, Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression, *Pharmacol Res* 61 (2010) 34–39.
- [89] M. Busch, S. Franke, C. Ruster, G. Wolf, Advanced glycation end-products and the kidney, *Eur J Clin Invest* 40 (2010) 742–755.
- [90] Q. Fan, J. Liao, M. Kobayashi, M. Yamashita, L. Gu, T. Gohda, Y. Suzuki, L.N. Wang, S. Horikoshi, Y. Tomino, Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice, *Nephrol. Dial. Transplant.* 19 (2004) 3012–3020.
- [91] S. Yamagishi, M. Takeuchi, H. Inoue, Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats, *Drugs Exp. Clin. Res.* 31 (2005) 45–51.
- [92] K. Sebekova, K. Gazdikova, D. Syrova, P. Blazicek, R. Schinzel, A. Heidland, V. Spustova, R. Dzurik, Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products, *J. Hum. Hypertens.* 17 (2003) 265–270.
- [93] Y. Saisho, N. Komiya, H. Hirose, Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan, *Diab. Res. Clin. Pract.* 74 (2006) 201–203.
- [94] E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, E. Ritz, R.C. Atkins, R. Rohde, I. Raz, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, *N. Engl. J. Med.* 345 (2001) 851–860.
- [95] P.C. Chang, T.H. Chen, C.J. Chang, C.C. Hou, P. Chan, H.M. Lee, Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway, *Kidney Int.* 65 (2004) 1664–1675.
- [96] X. Yu, C. Li, X. Li, L. Cai, Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1, *Toxicol. Sci.* 96 (2007) 346–356.
- [97] S.C. Tang, J.C. Leung, L.Y. Chan, A.W. Tsang, K.N. Lai, Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist, *J. Am. Soc. Nephrol.* 17 (2006) 1633–1643.
- [98] N. Marx, D. Walcher, N. Ivanova, K. Rautzenberg, A. Jung, R. Friedl, V. Hombach, R. de Caterina, G. Basta, M.P. Wautier, J.L. Wautiers, Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products, *Diabetes* 53 (2004) 2662–2668.
- [99] L. Wang, F.D. Cui, H. Sunada, Preparation and evaluation of solid dispersions of nifedipine prepared with fine silica particles using the melt-mixing method, *Chem Pharm Bull Tokyo* 54 (2006) 37–43.
- [100] S. Yamagishi, T. Matsui, K. Nakamura, M. Takeuchi, H. Inoue, Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation, *Protein Pept. Lett.* 15 (2008) 850–853.
- [101] T. Matsui, K. Nakamura, M. Takeuchi, S. Yamagishi, Telmisartan blocks advanced glycation end-product (AGE)-induced plasminogen activator inhibitor-1 gene expression in endothelial cells through activation of peroxisome proliferator-activated receptor-g, *Lett Drug Des Dis* 5 (2008) 477–480.
- [102] T. Matsui, S. Yamagishi, S. Ueda, K. Nakamura, T. Imaizumi, M. Takeuchi, H. Inoue, Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation, *J. Int. Med. Res.* 35 (2007) 482–489.
- [103] T. Yoshida, S. Yamagishi, K. Nakamura, T. Matsui, T. Imaizumi, M. Takeuchi, H. Koga, T. Ueno, M. Sata, Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation, *Diabetologia* 49 (2006) 3094–3099.
- [104] T. Yoshida, S. Yamagishi, T. Matsui, K. Nakamura, T. Ueno, M. Takeuchi, M. Sata, Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation, *J. Int. Med. Res.* 36 (2008) 237–243.
- [105] L. Ma, H.Q. Gao, B.Y. Li, Y.B. Ma, B.A. You, F.L. Zhang, Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by advanced glycation end products through activation of peroxisome proliferator-activated receptor gamma, *J. Cardiovasc. Pharmacol.* 49 (2007) 293–298.
- [106] T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, S. Okuda, Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation, *Biochem. Biophys. Res. Commun.* 385 (2009) 269–272.
- [107] J.J. Wang, S.X. Zhang, K. Lu, Y. Chen, R. Mott, S. Sato, J.X. Ma, Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy, *Diabetes* 54 (2005) 243–250.
- [108] J.J. Wang, S.X. Zhang, R. Mott, R.R. Knapp, W. Cao, K. Lau, J.X. Ma, Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities, *Diabetes* 55 (2006) 1678–1685.
- [109] S. Maeda, T. Matsui, M. Takeuchi, Y. Yoshida, R. Yamakawa, K. Fukami, S.-I. Yamagishi, Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis, *Pharmacol. Res.* (2011), in press.
- [110] T.C. Ho, S.L. Chen, Y.C. Yang, C.L. Liao, H.C. Cheng, Y.P. Tsao, PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells, *Cardiovasc. Res.* 76 (2007) 213–223.
- [111] T.C. Ho, Y.C. Yang, S.L. Chen, P.C. Kuo, H.K. Sytwu, H.C. Cheng, Y.P. Tsao, Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma, *Mol. Immunol.* 45 (2008) 898–909.
- [112] W.K. Bolton, D.C. Cattran, M.E. Williams, S.G. Adler, G.B. Appel, K. Cartwright, P.G. Foiles, B.I. Freedman, P. Raskin, R.E. Ratner, B.S. Spinowitz, F.C. Whittier, J.P. Wuerth, Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy, *Am. J. Nephrol.* 24 (2004) 32–40.
- [113] R. Bucala, K.J. Tracey, A. Cerami, Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes, *J. Clin. Invest.* 87 (1991) 432–438.
- [114] R. Bucala, R. Mitchell, K. Arnold, T. Innerarity, H. Vlassara, A. Cerami, Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor, *J. Biol. Chem.* 270 (1995) 10828–10832.
- [115] M.R. Hoernig, C. Bianchi, A. Rosenzweig, F.W. Sellke, Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1, *Curr. Mol. Med.* 8 (2008) 754–767.
- [116] Q. Chen, L. Dong, L. Wang, L. Kang, B. Xu, Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2, *Biochem. Biophys. Res. Commun.* 381 (2009) 192–197.
- [117] R.J. Scheubel, S. Kahrstedt, H. Weber, J. Holtz, I. Friedrich, J. Borgermann, R.E. Silber, A. Simm, Depression of progenitor cell function by advanced glycation endproducts (AGEs): potential relevance for impaired angiogenesis in advanced age and diabetes, *Exp. Gerontol.* 41 (2006) 540–548.
- [118] A.D. Bhatwadekar, J.V. Glenn, G. Li, T.M. Curtis, T.A. Gardiner, A.W. Stitt, Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodilation in diabetic retinopathy, *Invest Ophthalmol Vis Sci* 49 (2008) 1232–1241.
- [119] J. Chen, L. Huang, M. Song, S. Yu, P. Gao, J. Jing, C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells, *J. Cardiovasc. Pharmacol.* 53 (2009) 359–367.
- [120] T. Murohara, T. Asahara, M. Silver, C. Bauters, H. Masuda, C. Kalka, M. Kearney, D. Chen, J.F. Symes, M.C. Fishman, P.L. Huang, J.M. Isner, Nitric oxide synthase modulates angiogenesis in response to tissue ischemia, *J. Clin. Invest.* 101 (1998) 2567–2578.
- [121] H. Ueno, H. Koyama, S. Fukumoto, S. Tanaka, T. Shoji, T. Shoji, M. Emoto, H. Tahara, M. Inaba, R. Kakiya, T. Tabata, T. Miyata, Y. Nishizawa, Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease, *Metabolism*.
- [122] S. Yamagishi, H. Fujimori, H. Yonekura, N. Tanaka, H. Yamamoto, Advanced glycation endproducts accelerate calcification in microvascular pericytes, *Biochem. Biophys. Res. Commun.* 258 (1999) 353–357.
- [123] S.S. Shaw, A.M. Schmidt, A.K. Baner, X. Wang, D.M. Stern, M.B. Marrero, S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2, *Diabetes* 52 (2003) 2381–2388.
- [124] T. Sakaguchi, S.F. Yan, S.D. Yan, D. Belov, L.L. Rong, M. Sousa, M. Andrassy, S.P. Marso, S. Duda, B. Arnold, B. Liliensiek, P.P. Nawroth, D.M. Stern, A.M. Schmidt, Y. Naka, Central role of RAGE-dependent neointimal expansion in arterial restenosis, *J. Clin. Invest.* 111 (2003) 959–972.
- [125] A. Soro-Paavonen, A.M. Watson, J. Li, K. Paavonen, A. Koitka, A.C. Calkin, D. Barit, M.T. Coughlan, B.G. Drew, G.I. Lancaster, M. Thomas, J.M. Forbes, P.P. Nawroth, A. Bierhaus, M.E. Cooper, K.A. Jandeleit-Dahm, Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes, *Diabetes* 57 (2008) 2461–2469.
- [126] K. Asanuma, P. Mundel, The role of podocytes in glomerular pathobiology, *Clin. Exp. Nephrol.* 7 (2003) 255–259.